Cargando…

Safety and Tolerability of PCSK9 Inhibitors: Current Insights

The current era of preventive cardiology continues to emphasize on low-density lipoprotein cholesterol (LDL-C) reduction to alleviate the burden of atherosclerotic cardiovascular disease (ASCVD). In this regard, the pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosmas, Constantine E, Skavdis, Andreas, Sourlas, Andreas, Papakonstantinou, Evangelia J, Peña Genao, Edilberto, Echavarria Uceta, Rogers, Guzman, Eliscer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737942/ https://www.ncbi.nlm.nih.gov/pubmed/33335431 http://dx.doi.org/10.2147/CPAA.S288831

Ejemplares similares

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2022)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
por: Kosmas, Constantine E., et al.
Publicado: (2023)

The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease
por: Kosmas, Constantine E., et al.
Publicado: (2023)

Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Primary genetic disorders affecting high density lipoprotein (HDL)
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Therapeutic management of hyperlipoproteinemia (a)
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Insulin resistance and cardiovascular disease
por: Kosmas, Constantine E., et al.
Publicado: (2023)

Insight into the Evolving Role of PCSK9
por: Maligłówka, Mateusz, et al.
Publicado: (2022)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular Disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
por: Oleaga, Carlota, et al.
Publicado: (2020)

PCSK9 Inhibition: From Current Advances to Evolving Future
por: Liu, Chunping, et al.
Publicado: (2022)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
por: Katzmann, Julius L., et al.
Publicado: (2020)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Phage display for targeting PCSK9
por: Ferri, Nicola
Publicado: (2021)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

In Silico Insights into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
por: Martin, William R., et al.
Publicado: (2020)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cnvb2qbiuli4djqtv6bg4ski67